Prognostic factors in oligodendroglioma

Canadian Journal of Neurological Sciences

Volumn 24, Issue 4, 1997, Pages 313-319

  Schiffer, D ^a,d   Dutto, A ^a   Cavalla, P ^a   Bosone, I ^a   Chio A ^a   Villani, R ^b   Bellotti, C ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^d Department of Neuroscience   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APOPTOSIS; ARTICLE; BRAIN BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0031414699     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100032984     Document Type: Article

References (48)

1. Zülch KJ: Brain Tumours. Their Biology and Pathology. 3rd ed. Berlin-Heidelberg-New York-Tokyo: Springer, 1986.
2. Russell DS and Rubinstein LJ. Pathology of Tumours of the Nervous System. 5th ed. London: Arnold, 1989.
3. Cairncross JG. and Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988; 23: 360-364.
4. Glass J, Hochberg FH, Gruber ML, et al. The treatment of oligodendrogliomas and mixed oligoendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 1992; 76: 741-745.
5. Kyritsis AP, Yung WKA, Bruner J, Gleason MJ, Levin VA. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993; 32: 365-371.
6. Mason WP, Krol GS, De Angelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996; 46: 203-207.
7. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW. Grading of oligodendrogliomas. Cancer 1983; 52: 2107-2114.
8. Kros JM, Pieterman H, van Eden CG, Avezaat CJJ. Oligodendroglioma: the Rotterdam-Dijkzigt experience. Neurosurgery 1994; 34: 959-966.
9. Kros JM, Hop WCJ, Godschalk JCJ, Krishnadath KK. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996; 78: 1107-1113.
10. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992; 76: 428-434.
11. Mørk SJ, Halvorsen TB, Lindegaard K-F, Eide GE. Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 1986; 45: 65-78.
12. Burger PC, Rawlings CE, Cox EB, et al. Clinicopathologic correlations in the oligodendroglioma. Cancer 1987; 59: 1345-1352.
13. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994; 35: 1018-1035.
14. Coons SW and Johnson PC. MIB-1/Ki-67 labeling index predicts patient survival for oligodendroglial tumors. J Neuropathol Exp Neurol 1995; 24: 9-12.
15. Heegard S, Sommer HM, Broholm H, Broendstrup O. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 1995; 76: 1809-1813.
16. Kleihues P, Burger PC, Scheithauer BW. WHO. Histological Typing of Tumours of the Central Nervous System. 2nd ed. Berlin, Heidelberg, New York, etc. Springer, 1993, 19.
17. Bullard DE, Rawlings CE, Phillips B, et al. Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 1987; 60: 2179-2188.
18. Nijjar TS, Simpson WJ, Gadalla T, McCartney M. Oligodendroglioma. The Princess Margaret Hospital Experience (1958-1984). Cancer 1993; 71: 4002-4006.
19. Mørk SJ, Lindergaard K-F, Halvorsen TB, et al. Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 1985; 63: 881-889.
20. Daumas-Duport C, Scheithauer BW, O'Fallon J, Kelly P. Grading of astrocytomas: a simple and reproducible grading method. Cancer 1988; 62: 2152-2165.
21. Migheli A, Cavalla P, Marino S, Schiffer D: A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol 1994; 53: 606-616.
22. Herpers MJHM and Budka H. Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma. Acta Neuropathol 1984; 64: 265-272.
23. Schiffer D, Chiò A, Giordana MT, Pezzulo T, Vigliani MC. Proliferating cell nuclear antigen expression in brain tumors, and its prognostic role in ependymomas: an immunohistochemical study. Acta Neuropathol 1993; 85: 495-502.
24. Kaplan EL and Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
25. Segal MR. Regression trees for censored data. Biometrics 1988; 44: 35-47.
26. Peto R, Pike MG, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: analysis and examples. Br J Cancer 1977; 35: 1-39.
27. Cox DR. Regression models and life tables. J R Stat Soc 1972; B34: 187-220.
28. Earnest F, Kernohan JW, Craig WMcK. Oligodendrogliomas: a review of two hundred cases. Arch Neurol Psychiat 1950; 63: 964-976.
29. Kernohan JW. Oligodendrogliomas. In: Minckler J, ed. Pathology of the Nervous System. Vol 2, New York: Mc Graw-Hill, 1971: 1993-2007.
30. Weir B, Elvidge AR. Oligodendrogliomas: an analysis of 60 cases. J Neurosurg 1968; 29: 500-505.
31. Kernohan JW, Mabon RF, Svien HJ, Adson AW. A simplified classification of the gliomas. Proc Staff Meet Mayo Clinic 1949; 24: 71-75.
32. Schiffer D, Cavalla P, Pilkington GJ. Proliferative properties of malignant brain tumors. In: Mikkelsen T, Bjerkvig R, Laerum O and Rosemblum ML, eds. Brain Tumor Invasion: Biological, Clinical and Therapeutic considerations. John Wiley and Sons Inc, 1996.
33. Schiffer D, Cavalla P, Migheli A, Chiò A, Giordana MT. Apoptosis and cell proliferation in neuroepithelial tumors. Neurosci Lett 1995; 195: 81-84.
34. Lipponen PK and Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994; 173: 333-339.
35. Ellison DW, Steart PV, Gatter KC, Weller RO. Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 1995; 21: 352-361.
36. Khoshyomn S, Maier H, Morimura T, Kitz K, Budka H. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens. Acta Neuropathol 1993; 86: 582-589.
37. Karamitopoulou E, Perentes E, Melachrinou M, Maraziotis T. Proliferating cell nuclear antigen immunoreactivity in human central nervous system neoplasms. Acta Neuropathol 1993; 85: 316-322.
38. Shaw EG, Scheithauer BW, O'Fallon JR, Davis DH. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 1994; 34: 577-582.
39. de la Monte SM. Uniform lineage of oligodendrogliomas. Am J Pathol 1989; 135: 529-540.
40. Bishop M and de la Monte SM. Dual lineage of astrocytomas. Am J Pathol 1989; 135: 517-527.
41. von Diemling A, Louis DN, von Ammon K, et al. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytoma, oligodendroglioma and mixed glioma. Cancer Res 1992; 52: 4277-4279.
42. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Path 1994; 145: 1175-1189.
43. Kraus JA, Koopman J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995; 54: 91-95.
44. Kros JM, Godschalk JJCJ, Krishnadath KK, van Eden CG. Expression of p53 in oligodendrogliomas. J Pathol 1993; 171: 285-290.
45. Pavelic J, Hlavka V, Poljak M, Gale N, Pavelic K. p53 immunoreactivity in oligodendrogliomas. J Neuro-Oncol 1994; 22: 1-6.
46. Wu JK, Zhen Y, Darras BT. Frequency of p53 tumor suppressor gene mutations in human primary brain tumors. Neurosurgery 1993; 33: 824-831.
47. Louis DN, von Deimling A, Chung RY, et al. Comparative study of p53 gene and protein alterations in human astrocytic tumours. J Neuropathol Exp Neurol 1993; 52: 31-38.
48. Wallner KE, Gonzales M, Sheline GE. Treatment of oligodendrogliomas with or without postoperative irradiation. J Neurosurg 1988; 68: 684-688.